Figure 6From: Potentiating antilymphoma efficacy of chemotherapy using a liposome for integration of CD20 targeting, ultra-violet irradiation polymerizing, and controlled drug deliveryIn vivo antitumor activity of ADR-loaded liposomes. (A) Lymphoma-bearing SCID mice were treated with 5 mg/kg free ADR, PC-ADR-Fab, and PC-ADR-Fab; 24 h later, mice were euthanized and organs were harvested, washed, and weighed; and the ADR was extracted and quantified. (B) In vivo tumor accumulation profile of frozen section from lymphoma-bearing SCID mice treated with free ADR, PC-ADR-BSA, and PC-ADR-Fab for 24 h as visualized by confocal microscopy, the RED fluorescence represents the tumor accumulation and retention of ADR. Scale bar 50 μm. (C) In vivo anticancer therapeutic effects in localized human NHL xeno-transplant models after the first intravenous administration of PBS, free ADR, PC-ADR-BSA, and PC-ADR-Fab. Tumor volumes were measured every 3 days. Results are presented as mean ± SD of four separate mice in one group. →, treatment. (D) In vivo antitumor therapeutic effects in disseminated human NHL xeno-transplant models after the first intravenous administration of PBS, free ADR, PC-ADR-BSA, and PC-ADR-Fab. Survival curves were plotted with the Kaplan-Meier method and were compared by using a log-rank test.Back to article page